ライフサイエンスコーパス: leukopenia

1 the suppression of hematopoiesis (anemia and leukopenia).

2 mbers of HSCs and committed progenitors; and leukopenia.

3 ty of GM-CSF to reverse chemotherapy-induced leukopenia.

4 ors are used to reverse chemotherapy-induced leukopenia.

5 cer in a mouse model of chemotherapy-induced leukopenia.

6 e neutropenia, thrombocytopenia, anemia, and leukopenia.

7 ounced rescue of radiation-induced anemia or leukopenia.

8 nicity, treatment with immunomodulators, and leukopenia.

9 a new mutant strain, HLB368, with hereditary leukopenia.

10 All grade 4 toxicities were neutropenia or leukopenia.

11 rades 3 and 4 hepatotoxicity and neutropenia/leukopenia.

12 inducing only transient thrombocytopenia and leukopenia.

13 a corresponding increase in antigenemia and leukopenia.

14 illness included tachycardia, tachypnea, and leukopenia.

15 ausea or vomiting, diarrhea, stomatitis, and leukopenia.

16 A virus (IAV) results in a severe transient leukopenia.

17 , thrombocytopenia, anemia, lymphopenia, and leukopenia.

18 included a transient loss of body weight and leukopenia.

19 dache, and thrombocytopenia, with or without leukopenia.

20 Six of 20 patients had grade 3 leukopenia.

21 arrhea with hypotension, abdominal pain, and leukopenia.

22 reated patients with bacterial infection had leukopenia.

23 fever, hepatic dysfunction, and progressive leukopenia.

24 ic extramedullary hematopoiesis, anemia, and leukopenia.

25 ith 76% of courses resulting in grade 3 or 4 leukopenia.

26 oped vascular leakage, thrombocytopenia, and leukopenia.

27 e being intense fever, thrombocytopenia, and leukopenia.

28 clovir was tolerated without side effects or leukopenia.

29 syndrome, viral infections, and progressive leukopenia.

30 s of thiopurine metabolites, which can cause leukopenia.

31 had to be performed in 3 of 13 patients for leukopenia.

32 ions, can be complicated by life-threatening leukopenia.

33 lactate dehydrogenase production, and severe leukopenia.

34 he causal role of the mutant receptor in the leukopenia.

35 thrombocytopenia (3%), neutropenia (2%), and leukopenia (1%).

36 3) among all cohorts were neutropenia (16%), leukopenia (11%), anemia (9%), and diarrhea (7%).

37 e 3 adverse events were neutropenia (24.5%), leukopenia (14.3%), and thrombocytopenia (12.2%).

38 31 (26%) patients experiencing grade 3 to 4 leukopenia; 15 of 31 patients (48%) experienced grade 3

39 3 adverse events included neutropenia (39%), leukopenia (16%), anemia (14%), and diarrhea (13%); the

40 enia (47%), neutropenia (32%), anemia (27%), leukopenia (16%), fatigue (11%), and hyponatremia (10%).

41 notable complications were infections (17%), leukopenia (18%), cardiovascular events (13%), and malig

42 were mucositis (49%), dermatitis (21%), and leukopenia (18%).

43 oxicities were as follows: neutropenia, 64%; leukopenia, 18%; fatigue, 5%; peripheral neuropathy, 5%;

44 e most frequently reported (7%), followed by leukopenia (2%).

45 ion, 20 patients (4.6%) developed persistent leukopenia, 2 patients (0.5%) were diagnosed as having p

46 lib group vs. 0.9% in the placebo group) and leukopenia (21.0% vs. 0.6%); the rates of discontinuatio

47 enia (67%), neutropenia (36%), anemia (28%), leukopenia (22%), and fatigue (11%).

48 (32%), neutropenia (27%), anemia (23%), and leukopenia (23%) reported.

49 utropenia (43%), thrombocytopenia (36%), and leukopenia (23%).

50 Grade 3 toxicities were leukopenia (24%), infection (22%), peripheral neuropathy

51 ts were neutropenia (78%), anemia (28%), and leukopenia (24%).

52 mbocytopenia (13% v 29%), anemia (7% v 15%), leukopenia (26% v 25%), and neuropathy (1% v 5%).

53 han grade 2 toxicities were neutropenia 35%, leukopenia 28%, and metabolic 28%.

54 included fatigue (22%), infection (9%), and leukopenia (3%).

55 was mucositis (17%); the only grade 4 AE was leukopenia (3%).

56 42 patients, seven with grade 3/4 toxicity), leukopenia (33 patients, nine with grade 3/4 toxicity),

57 In group 1, neutropenia (50%) and leukopenia (35%) necessitated dose reductions for 50% of

58 >/=3 toxicities included neutropenia (70%), leukopenia (36%), and lymphopenia (20%).

59 oxicity was primarily hematologic, including leukopenia (46%), thrombocytopenia (13%), and anemia (28

60 r grade 3 toxicities were neutropenia (52%), leukopenia (48%), gastrointestinal (24%), neurologic (18

61 The predominant grade 3 to 4 toxicities were leukopenia (49%), granulocytopenia (55%), and thrombocyt

62 ing more than once included neutropenia (8), leukopenia (5), and lymphopenia (2).

63 st common grades 3 and 4 toxicities included leukopenia (50%), thrombocytopenia (23%), and esophagiti

64 e events included neutropenia (n=107 [43%]), leukopenia (53 [21%]), and anaemia (26 [10%]).

65 to 4 adverse events were neutropenia (63%), leukopenia (54%), anemia (35%), thrombocytopenia (33%),

66 in the chemoradiotherapy-surgery group were leukopenia (6%) and neutropenia (2%); the most common ma

67 (11%), diarrhea (8%), lymphopenia (8%), and leukopenia (6%).

68 The combination produced more grade 3 to 4 leukopenia (62% v 40%), thrombocytopenia (14% v 2%), ane

69 /R+ patients, there was a lower incidence of leukopenia (67% vs. 82%, P=0.039) and trend toward less

70 e 3 or 4 adverse events were mucositis (9%), leukopenia (7%), hyperglycemia (7%), somnolence (6%), th

71 st common toxicities were neutropenia (96%), leukopenia (84%), thrombocytopenia (82%), anemia (74%),

72 eutropenia (199/689 [29%] vs 164/690 [24%]), leukopenia (99/689 [14%] vs 77/690 [11%]), and febrile n

73 Leukopenia after kidney transplant increased the risk of

74 end points were the incidence of stomatitis, leukopenia, alopecia, diarrhea, nausea, and vomiting, re

75 le sex, treatment with immunomodulators, and leukopenia also influenced the risk of pneumonia.

76 ion between mycophenolate-related anemia and leukopenia and 2724 single nucleotide polymorphisms (SNP

77 worse in our 5-FU-treated patients, profound leukopenia and a need for unplanned hospitalization were

78 while the latter peak was attenuated only by leukopenia and augmented in the accelerated form of this

79 il was associated with a higher incidence of leukopenia and diarrhea, often leading to discontinuatio

80 There were significantly more leukopenia and gastrointestinal adverse events in the MM

81 Leukopenia and gastrointestinal side effects were the mo

82 icant adverse events occurred, although mild leukopenia and increases in aminotransferase activity we

83 hAAT significantly reduced infection-induced leukopenia and liver, pancreas, and lung injury, and it

84 Nonsurvivors were immunosuppressed with leukopenia and markedly reduced tumor necrosis factor-al

85 xicities were hematologic; and acute grade 4 leukopenia and neutropenia occurred in 30.2% and 34.0% o

86 late-onset CMV infections and side effects (leukopenia and neutropenia) than the preemptive strategy

87 atients in the standard arm had grade 3 to 4 leukopenia and neutropenia, but there were more instance

88 ngenital disorder that causes severe chronic leukopenia and neutropenia.

89 They had significant leukopenia and reduced delayed-type hypersensitivity res

90 toms of systemic lupus erythematosus such as leukopenia and renal insufficiency.

91 Younger patients experienced less leukopenia and stomatitis, but more frequent nausea/vomi

92 The incidences of perioperative leukopenia and thrombocytopenia were lower in the outpat

93 ls expressing Delta4 initially suffered from leukopenia and thrombocytopenia.

94 g factor (G-CSF) is used clinically to treat leukopenia and to enforce hematopoietic stem cell (HSC)

95 t myelosuppression of grade 3 or 4 in 15.3% (leukopenia) and 7.6% (thrombocytopenia) of applied cycle

96 eukopenia (eight patients had > or = grade 4 leukopenia) and anemia.

97 Four patients experienced grade 2 or 3 leukopenia, and 2 had grade 4 lymphopenia.

98 er, fatigue, diarrhea, thrombocytopenia, and leukopenia, and both had been bitten by ticks 5 to 7 day

99 lude flu-like symptoms with fever, diarrhea, leukopenia, and elevated liver enzymes.

100 we assessed Medicare claims for neutropenia, leukopenia, and GCSF use, respectively.

101 Neutropenia, leukopenia, and hypotension occurred more frequently in

102 rombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level

103 ersible elevations in hepatic transaminases, leukopenia, and lymphopenia.

104 related grade 3 or 4 toxicities were anemia, leukopenia, and neutropenia (19% each); lymphopenia (14%

105 , hypotonia and sometimes with polycythemia, leukopenia, and neutropenia.

106 Mice additionally presented anemia, leukopenia, and splenomegaly.

107 Disseminated infection, leukopenia, and the height of the serum galactomannan in

108 Anemia, neutropenia, leukopenia, and thrombcytopenia were 11%, 32%, 52%, and

109 He was hospitalized with fever, confusion, leukopenia, and thrombocytopenia and developed multiorga

110 For 177Lu-EDTMP, anemia, leukopenia, and thrombocytopenia were nonserious (grade

111 For 153Sm-EDTMP, anemia, leukopenia, and thrombocytopenia were nonserious (grade

112 ntolerance, aminotransferase level increase, leukopenia, and thrombocytopenia.

113 d in Missouri that is associated with fever, leukopenia, and thrombocytopenia.

114 r patients with thrombocytopenia, three with leukopenia, and two with anemia.

115 ity indicators, such as cardiac hypertrophy, leukopenia, and weight and hair loss were not detected w

116 Leukopenia, anemia, and allograft nephrotoxicity were ad

117 opoietic cells leads to bone marrow aplasia, leukopenia, anemia, and early lethality.

118 Grade 3-4 neutropenia, leukopenia, anemia, and thrombocytopenia occurred in a s

119 yalgias, chills, and varying combinations of leukopenia, anemia, and thrombocytopenia.

120 nt-emergent adverse events were neutropenia, leukopenia, anemia, thrombocytopenia, and fatigue.

121 Thrombocytopenia and leukopenia are not infrequent occurrences with SRL treat

122 Mycophenolate-related anemia and leukopenia are well-known toxicities after transplantati

123 though hyperlipidemia, neutropenia, fatigue, leukopenia, arthralgia, and diarrhea were more frequent

124 tion, ATMIN-deficient mice developed chronic leukopenia as a result of high levels of apoptosis in B

125 ith enhanced responses to Cxcl12 and exhibit leukopenia as reported in patients.

126 ts to the occurrence of thrombocytopenia and leukopenia, as well as the severity and the time- and co

127 n high-risk RTR, with a reduced incidence of leukopenia associated with the low-dose regimen and no d

128 one of the SNPs were associated with time to leukopenia at a false discovery rate (FDR) of 20%.

129 p a syndrome of severe thrombocytosis-anemia-leukopenia because of significant increases in megakaryo

130 el, GM-CSF reversed cyclophosphamide-induced leukopenia but also promoted breast cancer and prostate

131 ounts than those of European descent (ethnic leukopenia), but whether this impacts negatively on HIV-

132 There was also significantly more leukopenia, but a greater percentage of T-regulatory cel

133 ytic ehrlichiosis (HGE) developed anemia and leukopenia, but by day 24, they returned to normal value

134 benefits of this growth factor in reversing leukopenia caused by treatment with chemotherapy.

135 he persistence, of both thrombocytopenia and leukopenia correlated significantly with SRL trough conc

136 ter adjustment for age, sex, smoking status, leukopenia, corticosteroid use, and diabetes mellitus.

137 Reversible leukopenia (decline in white blood cell count to <3.0 x

138 nd only Grade 1 thrombocytopenia and Grade 2 leukopenia developed after the second injection, both re

139 ); neutropenia (n = 7); fatigue (n = 4); and leukopenia, diarrhea, and pain (n = 3 each).

140 ost common grade 3 and 4 adverse events were leukopenia (eight [32%]) and neutropenic infections (fiv

141 Major toxicities of therapy were leukopenia (eight patients had > or = grade 4 leukopenia

142 bed association of this genotype with ethnic leukopenia extends to HIV-infected African Americans (AA

143 toxicities were anemia, acne-like skin rash, leukopenia, fatigue and malaise, and nausea and vomiting

144 ties from IL-2 were mainly thrombocytopenia, leukopenia, fever, and fluid retention.

145 ia, anemia, diarrhea, nausea, rigors/chills, leukopenia, fever, and transaminase elevation.

146 were hematologic, including neutropenia and leukopenia followed by neuropathy, myalgia, nausea, fati

147 s having EC-MPS withheld/discontinued due to leukopenia, gastrointestinal symptoms, and infection wer

148 milar in both arms, except for grades 3 to 4 leukopenia (GD, 78%; CD, 66%; P = .025) and transfusions

149 ntensification regimen consisted of grade IV leukopenia, grade IV thrombocytopenia, and febrile neutr

150 CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as w

151 The most common toxicities were anemia, leukopenia/granulocytopenia, malaise/fatigue, nausea/vom

152 Leukopenia (>/= grade 3) occurred in 10% of chemotherapy

153 d in patients with anemia, thrombocytopenia, leukopenia, higher blast count, symptoms, large splenome

154 Less prominent reactions included leukopenia, hypertriglyceridemia, and hypercalcemia.

155 4 toxicities occurring in any cycle included leukopenia, hypophosphatemia, asthenia, anemia, and hype

156 (11.3%) and 29 administrations (4.6%), with leukopenia in 2.7% and thrombocytopenia in 1.7%.

157 Anemia occurred in 87 (9.5%) subjects and leukopenia in 224 (22.9%).

158 openia both occurring in 41% of patients and leukopenia in 23%.

159 (grade 3 and 4) included neutropenia in 42%, leukopenia in 25%, anemia in 15%, and constitutional in

160 Thrombocytopenia was observed in 70%, leukopenia in 59%; lymphopenia in 45%; and elevated leve

161 a was reported in 87 cycles (31%), grade 3-4 leukopenia in 77 (28%), and grade 3-4 thrombocytopenia i

162 ic circulatory shock, hyperlactacidemia, and leukopenia in a dose-related fashion.

163 cogenetic determinant for thiopurine-induced leukopenia in diverse populations.

164 tive analysis of timing, degree, and type of leukopenia in four groups of patients: cases (n=20); con

165 We induced leukopenia in guinea pigs with vinblastine (0.7 mg/kg, i

166 Mutations in CXCR4 cause severe leukopenia in myelokathexis or WHIM syndrome.

167 mong the elderly (age >70 years), except for leukopenia in one study.

168 e rendered neutropenic develop a generalized leukopenia in response to these three infections.

169 strongly associated with thiopurine-induced leukopenia in subjects with inflammatory bowel disease o

170 Lethality was associated with more severe leukopenia in transgenic versus control mice.

171 were available for four patients, revealing leukopenia in two, lymphopenia in one, and thrombocytope

172 , respectively, for thiopurine-induced early leukopenia (in comparison to 12.1% and 97.6% for TPMT va

173 ildren with recurrent infections, congenital leukopenia including neutropenia, B and T cell lymphopen

174 , but immunologic stress conditions inducing leukopenia increase the demand for peripheral blood cell

175 IV but was the most active at preventing the leukopenia induced by TNF alpha in mice, providing more

176 t treatment with N-acetylcysteine, or severe leukopenia induced by vinblastine.

177 cytopenia, prolonged bleeding times, anemia, leukopenia, infertility, cardiomyopathy, and shortened l

178 This leukopenia is associated with genetic variation in TPMT

179 Asians, the incidence of thiopurine-induced leukopenia is higher in Asians than in individuals of Eu

180 use of severe adverse drug reactions (ADRs); leukopenia is one of the most serious ADRs.

181 32.6%, P = 0.049) and a higher incidence of leukopenia less than 2000/mm (28.6% vs 9.8%; P = 0.001)

182 IV-infected subjects, we show that, although leukopenia (< 4000 WBC/mm(3) during infection) was assoc

183 -dependent thrombocytopenia (<61%, p < .05), leukopenia (<60%, p < .05), and mortality rate (50% at 5

184 were compatible with laboratory findings of leukopenia, lymphopenia, and thrombocytopenia.

185 zziness, myalgias, abdominal pain, anorexia, leukopenia, lymphopenia, thrombocytopenia, or elevated l

186 veloping CMV disease, the rate and extent of leukopenia may be reduced.

187 Leukopenia may confound population studies that estimate

188 ddl use was associated with less leukopenia (mean nadir, 3.33 v 1.49 x 10(3)/microL; p =

189 Profound hypotension, leukopenia, metabolic acidosis, renal impairment, thromb

190 say were evaluated in an in vivo LPS-induced leukopenia model in mice.

191 rombocytopenia (n = 5), neutropenia (n = 2), leukopenia (n = 1), and transient ischemic attack (n = 1

192 es simplex stomatitis associated with severe leukopenia (n = 1), asymptomatic leukopenia (n = 2), nau

193 pancreatitis (n = 1), and pneumonia without leukopenia (n = 1).

194 with severe leukopenia (n = 1), asymptomatic leukopenia (n = 2), nausea/ diarrhea (n = 2), thinning o

195 nd ulcers (n=2)] or bone marrow suppressive [leukopenia (n=9), anemia (n=6), and thrombocytopenia (n=

196 de 3 and 4 adverse events were hyperlipemia, leukopenia, nausea, vomiting, pneumonia, dyspnea, anemia

197 d a significantly lower rate of grade 3 to 4 leukopenia, neutropenia, and stomatitis and a lower rate

198 ost common toxicities were myelosuppression (leukopenia, neutropenia, and thrombocytopenia) and eleva

199 The most frequent grade 3/4 toxicities were leukopenia, neutropenia, anemia, thrombocytopenia, and n

200 Grade 4 leukopenia, neutropenia, febrile neutropenia, and enceph

201 dverse events were hand-foot syndrome (29%), leukopenia/neutropenia (24%), and fatigue (19%).

202 1 (56%) developed grade 3 or 4 toxicity with leukopenia/neutropenia, nausea/vomiting, and metabolic t

203 Grade 3 or 4 toxicities included leukopenia/neutropenia, thrombocytopenia, elevation of a

204 ent-related grade 3 to 4 toxicities included leukopenia/neutropenia, transient elevation of aminotran

205 Bacterial loads, MODS, leukopenia, neutrophil infiltration, immune cell activat

206 Only five episodes of grade III leukopenia occurred (14% of patients, 2% of doses), and

207 Grade III to IV leukopenia occurred in 32% of patients; 63% received pla

208 Grade 3/4 leukopenia occurred in 53% of patients, but only six pat

209 Grade 3 or 4 leukopenia occurred in 73% of patients in the ST arm and

210 For regimen B, severe leukopenia occurred in 86% to 100%, with febrile neutrop

211 Greater incidence of leukopenia occurred in group II at month 1 only (P=0.002

212 3 or 4 hematologic toxicity was common, with leukopenia occurring in 41.2% (grade 3, 29%; grade 4, 12

213 tive antineoplastic agent; however, grade IV leukopenia occurs in the large majority of patients trea

214 gly associated with thiopurine-induced early leukopenia (odds ratio (OR) = 35.6; P(combined) = 4.88 x

215 also 11% more likely than men to experience leukopenia of common toxicity criteria grade >/= 1, (70%

216 atients on carboplatin plus paclitaxel), and leukopenia (one patient on carboplatin plus paclitaxel).

217 (P = 0.003), tachypnea (OR 1.9, P = 0.001), leukopenia or leukocytosis (total white blood cell count

218 Safety review of leukopenia or thrombocytopenia did not differ.

219 Leukopenia or thrombocytopenia was seen in 82% of patien

220 patients who had fever accompanied by marked leukopenia or thrombocytopenia were serologically confir

221 Leukopenia (OR = 1.97; 95% CI, 1.39-2.79; P = .0001; Q =

222 , bacteremia (OR = 2.8; 95% CI, 2.3 to 3.6), leukopenia (OR = 2.5, 95% CI, 1.6 to 3.7), and multiloba

223 Each patient had thrombocytopenia, leukopenia, or both.

224 ity (>29.6 GBq) was associated with relevant leukopenia (P < 0.001).

225 leukopenia was 67% compared with 4% without leukopenia (p < 0.01).

226 PM 5-FU concentrations correlated with worse leukopenia (P = .04) and severity of mucositis (P = .04)

227 associated with the incidence and degree of leukopenia (P = 0.02) and thrombocytopenia (P = 0.03).

228 Grade 3 and 4 leukopenia (P =.002) and neutropenia (P =.008) occurred

229 ug-related G3 and G4 events included anemia, leukopenia, pancytopenia, nausea, hyperbilirubinemia, hy

230 ed cause of reversible refractory anemia and leukopenia, particularly neutropenia, often misdiagnosed

231 ing was targeted in group II to avoid severe leukopenia previously seen with alemtuzumab.

232 to 10.6 nmol/L, and correlated strongly with leukopenia ( r = .85).

233 Cyclophosphamide-mediated leukopenia reduced the size of the bacterial challenge d

234 provide a partial explanation of why ethnic leukopenia remains benign in HIV-infected AAs, despite i

235 Leukopenia, renal toxicity, peripheral neurotoxicity, an

236 ts experienced anemia, thrombocytopenia, and leukopenia, respectively.

237 ts experienced anemia, thrombocytopenia, and leukopenia, respectively.

238 c fevers (VHFs), including thrombocytopenia, leukopenia, skin and internal organ hemorrhages, high vi

239 3 to 4 neutropenia, febrile neutropenia, and leukopenia than etoposide-carboplatin; grade 3 to 4 thro

240 ious adverse events, but more frequent early leukopenia than induction with Atgam.

241 gimen experienced more severe stomatitis and leukopenia than men.

242 y acquire clinical symptoms of lupus such as leukopenia, thrombocytopenia and renal dysfunction.

243 system, and its use has resulted in cases of leukopenia, thrombocytopenia, and aplastic anemia.

244 H7N9 patients had similar patterns of leukopenia, thrombocytopenia, and elevated alanine amino

245 ehrlichioses with fever, headache, myalgias, leukopenia, thrombocytopenia, and elevated liver enzyme

246 l findings include fever, headache, myalgia, leukopenia, thrombocytopenia, and hepatic inflammatory i

247 CsA dose delivered (34.6 mg/kg) were anemia, leukopenia, thrombocytopenia, and hypertension.

248 Significant leukopenia, thrombocytopenia, and peripheral neuropathy

249 Leukopenia, thrombocytopenia, gastrointestinal symptoms,

250 iated with thrombocytosis, thrombocytopenia, leukopenia, venous thromboembolism, hyposplenism, and Ig

251 while the overall incidence of grade 3 or 4 leukopenia was 21.5% of patients.

252 Mortality associated with leukopenia was 67% compared with 4% without leukopenia (

253 The incidence of nephrotic syndrome and leukopenia was also lower in cluster 1 than in cluster 2

254 The incidence of grade 4 leukopenia was higher in patients with prior pelvic radi

255 Severe or life-threatening leukopenia was more common in the HU group (24%) than in

256 Leukopenia was more common with Thymoglobulin than Atgam

257 % of patients, 2% of doses), and no grade IV leukopenia was produced.

258 DLT (grade 3 stomatitis, diarrhea, leukopenia) was observed in cohorts 1, 2, and 4.

259 Thrombocytopenia and leukopenia were also observed.

260 Hypothermia, bradycardic hypotension, and leukopenia were most severe and prolonged in BDL + LPS r

261 received regimen A induction, grades 3 and 4 leukopenia were observed in 50% to 65%, with one toxicit

262 bronchitis, tooth infection, stomatitis, and leukopenia were reported.

263 therapy pretransplant and the occurrence of leukopenia were risk factors (OR per year, 1.192 [95% CI

264 Thrombocytopenia and leukopenia were the dose-limiting toxicities.

265 Neutropenia and leukopenia were the most common grade 3 and 4 toxicities

266 Hypertriglyceridemia and leukopenia were the most frequent adverse events, occurr

267 Stomatitis, diarrhea, and leukopenia were the predominant chemotherapy toxicities.

268 , and metabolic toxicity, as well as grade 4 leukopenia, were significantly more frequent in arm I.

269 The most common adverse effect was leukopenia, which occurred in 40% of patients.

270 The principal toxicity was leukopenia, which occurred with rapid onset and brief du

271 uated by decomplementation, neutropenia, and leukopenia, while the latter peak was attenuated only by

272 oglobin<10 gm/dL or hematocrit<30%) or first leukopenia (white blood cell [WBC] count <3000 cells/mm)

273 (platelet count <150x10(3) cell/mm3) and/or leukopenia (white blood cell count <5,000/mm3).

274 s included grade 2 transaminitis and grade 4 leukopenia with a grade 3 infection.

275 possible mechanisms behind this IAV-induced leukopenia with emphasis on the potential induction of a

276 a weak tendency to increased neutropenia and leukopenia with higher ganciclovir exposure.

277 Leukopenia with neutropenia developed in each patient, a

278 tients presenting with refractory anemia and leukopenia with or without associated neurologic deficit

279 vere cytopenia was observed in all patients; leukopenia (with median leukocyte count of 1400/mm3) was

280 The major toxicity was leukopenia, with 61% of patients who had grade 3 or 4.

281 generally mild: only 25 patients experienced leukopenia, with a median WBC count of 2,900 (range, 800

282 Infection was defined as leukocytosis or leukopenia, with a positive culture requiring either med

283 nificant difference occurred in incidence of leukopenia, with higher rates for AC-T-H versus AC-T (od

284 d mice exhibited anemia, thrombocytosis, and leukopenia, with pronounced pan-lymphopenia as demonstra

285 y utilized for CMV prophylaxis but can cause leukopenia, with risk compounded by the use of myelosupp